ARCHIVES

FDA Backs Down, Releases INDs, But Revives Controversy Over Clinical Testing Guidelines

This article is from The Cancer Letter archive.

Vol. 02 No. 11 | March 12, 1976

Download PDF Visit The Full Archive

Related Articles

Wyden Asks Bristol For documentation To Prove That Taxol Price Is Not “Gouging” Taxpayers

January 29, 1993

Elderly Patients Fail To Receive New Cancer Therapy For CML

August 27, 2010

2015: “A Challenge For Our Generation,” AACR Says

July 18, 2003

ODAC Recommends Fludarabine Approval for Refractory CLL

September 21, 1990

FDA Should Delay Provenge Decision Pending Definitive Trial Results, ODAC Chairman Writes.

April 27, 2007

Has To Plan International Meeting On Threat If DNA Biohazards

September 13, 1974